Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Relay Therapeutics, Inc. - Common Stock (NQ: RLAY )

4.000 +0.040 (+1.01%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Relay Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Relay Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Earnings Outlook For Relay Therapeutics
Via Benzinga
Relay Therapeutics to Announce Second Quarter 2023 Financial Results and Corporate Highlights on August 8, 2023
From Relay Therapeutics, Inc.
Via GlobeNewswire
InMode, Daktronics, Domino's Pizza And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones gaining around 250 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
11 Analysts Have This to Say About Relay Therapeutics
Via Benzinga
Relay Therapeutics: Q1 Earnings Insights
Via Benzinga
Earnings Outlook For Relay Therapeutics
Via Benzinga
The Global Metastatic Breast Cancer Treatment Market Expected To Reach $31 Billion By 2028
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:PFE),(NASDAQ:OCEA),(NYSE:NVS),(NASDAQ:RLAY) EQNX::TICKER_END 
Via FinancialNewsMedia
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
Data from FGFRi-naïve FGFR2-fusion CCA patients represent subset of September 2022 presentation and remain consistent with previously reported results 
From Relay Therapeutics, Inc.
Via GlobeNewswire
What 11 Analyst Ratings Have To Say About Relay Therapeutics
Via Benzinga
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics Reports First Quarter 2023 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics to Announce First Quarter 2023 Financial Results and Corporate Highlights
From Relay Therapeutics, Inc.
Via GlobeNewswire
Looking To Invest In Artificial Intelligence? Consider Evogene And Its Five Subsidiaries
Evogene employs an artificial intelligence platform for decoding plant phenotypes and microbial genomes. Consider its' research agenda, applications, and at-the-market products. The set-up may present... 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2023
Via Benzinga
Why Relay Therapeutics Stock Is Trading Higher Today
Relay Therapeutics (NASDAQ: RLAY) shares are trading higher after Raymond James upgraded the stock from Outperform to Strong Buy and announced a $29 price target. Also, the stock is rebounding... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 19, 2023
Via Benzinga
Relay Therapeutics to Participate in Two Upcoming Investor Conferences
From Relay Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 91 stocks hit new 52-week lows. 
Via Benzinga
Why Relay Therapeutics Stock Is Plunging Today
Relay Therapeutics Inc (NASDAQ: RLAY) announced initial clinical data for RLY-2608, an investigational allosteric, pan-mutant, and isoform-selective inhibitor of PI3Kα. 
Via Benzinga
Ericsson, Johnson & Johnson, Goldman Sachs And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Why Glory Star New Media Group Shares Are Trading Higher By 122%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) shares jumped 122% to $1.07 after the company announced the signing of a $60 million strategic investment with two institutional... 
Via Benzinga
Relay Therapeutics Announces Initial Clinical Data Demonstrating that RLY-2608 Selectively Targets Multiple PI3Kα Mutations
From Relay Therapeutics, Inc.
Via GlobeNewswire
Relay Therapeutics' Stock Price Premium Vs Peers Is Justified By Its Platform Technology, Analyst Says
Via Benzinga
Get In Now. 7 Stocks That Are Set to Soar.
While it’s always difficult to determine which stocks to buy might break out imminently, speculators should watch these ideas. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2023
Via Benzinga
Evolution of Oncology Treatments Giving New Hope to Those Diagnosed with Breast Cancer
FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group – Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs... 
Via FinancialNewsMedia
Evogene Offers An Excellent Risk/Reward Ratio
We think the company’s main CPB computational engine has the potential to be an extraordinary value creation engine. Investors only need one of the company's subsidiaries to succeed, to de-risk their... 
Via Talk Markets
Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
Relay Therapeutics to host conference call following AACR presentation 
From Relay Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.